Prognosis
Oxford-AstraZeneca Vaccine Effective But Questions Remain for Elderly
- Shot prevents severe disease, but more data needed on over-55s
- Detailed trial results published in The Lancet medical journal
This article is for subscribers only.
On the day Britain began immunizing its population with a Covid-19 shot developed by Germany’s BioNTech SE and the U.S.’s Pfizer Inc., a peer-reviewed study of the U.K.’s homegrown vaccine left some key questions unanswered.
While trial results published Tuesday in The Lancet found that a vaccine developed by the University of Oxford and AstraZeneca Plc is safe and effective, more analysis will be needed to see how well it works in people over 55, among those at higher risk from the pandemic.